Cumberland Pharmaceuticals (CPIX)
Cumberland Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
336K
Short interest
settlement 2026-10-15
9.0
Days to cover
+1.5 days vs prior
16.4%
Short share of volume
2026-10-28
105
Fails to deliver
settlement 2026-09-30
Tue 3 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CPIX is 336,001 shares, up 83,550 shares over the last month. Over the last 48 readings it ranged from 6,441 shares (15 July 2025) to 1,468,162 shares (13 December 2024). At the reported average volume of 37K shares a day that is 9.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/cpix" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 336,001 | -3.7% | 37,423 | 8.98 |
| 2026-09-30 | 348,880 | +38.2% | 46,316 | 7.53 |
| 2026-09-15 | 252,451 | -8.1% | 31,265 | 8.07 |
| 2026-08-31 | 274,685 | -15.8% | 90,801 | 3.03 |
| 2026-08-14 | 326,215 | -15.6% | 121,638 | 2.68 |
| 2026-07-31 | 386,521 | +3.7% | 138,640 | 2.79 |
| 2026-07-15 | 372,727 | +53.8% | 93,424 | 3.99 |
| 2026-06-30 | 242,415 | -28.4% | 47,587 | 5.09 |
| 2026-06-15 | 338,806 | -4.5% | 54,166 | 6.25 |
| 2026-05-29 | 354,906 | -22.0% | 168,982 | 2.10 |
| 2026-05-15 | 454,750 | -13.1% | 179,857 | 2.53 |
| 2026-04-30 | 523,399 | +363.6% | 4,873,175 | 1.00 |
| 2026-04-15 | 112,896 | +2.9% | 42,909 | 2.63 |
| 2026-03-31 | 109,732 | -23.1% | 57,896 | 1.90 |
| 2026-03-13 | 142,752 | -21.0% | 144,925 | 1.00 |
| 2026-02-27 | 180,766 | -6.5% | 127,471 | 1.42 |
| 2026-02-13 | 193,232 | +153.8% | 222,780 | 1.00 |
| 2026-01-30 | 76,121 | -24.5% | 180,744 | 1.00 |
| 2026-01-15 | 100,832 | -28.3% | 240,267 | 1.00 |
| 2025-12-31 | 140,686 | +360.2% | 287,104 | 1.00 |
| 2025-12-15 | 30,568 | +24.7% | 182,161 | 1.00 |
| 2025-11-28 | 24,522 | -28.0% | 57,827 | 1.00 |
| 2025-11-14 | 34,075 | -31.5% | 79,766 | 1.00 |
| 2025-10-31 | 49,726 | -6.9% | 34,992 | 1.42 |
| 2025-10-15 | 53,389 | -2.1% | 29,674 | 1.80 |
| 2025-09-30 | 54,551 | +21.1% | 28,332 | 1.93 |
| 2025-09-15 | 45,028 | -14.8% | 37,644 | 1.20 |
| 2025-08-29 | 52,834 | -1.5% | 28,280 | 1.87 |
| 2025-08-15 | 53,636 | +153.4% | 99,160 | 1.00 |
| 2025-07-31 | 21,166 | +228.6% | 62,604 | 1.00 |
| 2025-07-15 | 6,441 | -24.5% | 104,053 | 1.00 |
| 2025-06-30 | 8,532 | -87.5% | 154,878 | 1.00 |
| 2025-06-13 | 68,133 | +8.6% | 34,251 | 1.99 |
| 2025-05-30 | 62,724 | -20.6% | 44,319 | 1.42 |
| 2025-05-15 | 78,982 | -8.4% | 29,339 | 2.69 |
| 2025-04-30 | 86,188 | -39.0% | 28,675 | 3.01 |
| 2025-04-15 | 141,412 | -37.4% | 30,253 | 4.67 |
| 2025-03-31 | 225,972 | -22.9% | 61,940 | 3.65 |
| 2025-03-14 | 293,183 | -6.5% | 230,736 | 1.27 |
| 2025-02-28 | 313,581 | -37.4% | 321,266 | 1.00 |
| 2025-02-14 | 500,699 | +161.4% | 8,392,290 | 1.00 |
| 2025-01-31 | 191,571 | -56.3% | 40,750 | 4.70 |
| 2025-01-15 | 438,812 | -8.3% | 924,024 | 1.00 |
| 2024-12-31 | 478,433 | -67.4% | 218,909 | 2.19 |
| 2024-12-13 | 1,468,162 | +793.5% | 10,694,956 | 1.00 |
| 2024-11-29 | 164,315 | +83.4% | 290,317 | 1.00 |
| 2024-11-15 | 89,608 | +16.8% | 109,119 | 1.00 |
| 2024-10-31 | 76,744 | +89.3% | 46,865 | 1.64 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of CPIX volume is 16.4%, down 18.5 points over the last five sessions. Over the last 30 readings it ranged from 16.3% (2 October 2026) to 90.2% (13 October 2026). The latest reading sits at the bottom of that range. The latest reading is 28.6 points below the 30-session average of 45.0%, on 59K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 10K | 59K | 16.4% | 0 |
| 2026-10-27 | 91K | 291K | 31.3% | 25,316 |
| 2026-10-26 | 94K | 185K | 50.9% | 32,976 |
| 2026-10-23 | 3K | 5K | 56.4% | 0 |
| 2026-10-22 | 8K | 13K | 65.0% | 0 |
| 2026-10-21 | 21K | 59K | 34.9% | 0 |
| 2026-10-20 | 20K | 46K | 42.9% | 3,939 |
| 2026-10-19 | 10K | 40K | 24.1% | 403 |
| 2026-10-16 | 24K | 55K | 44.3% | 1,162 |
| 2026-10-15 | 4K | 16K | 25.2% | 0 |
| 2026-10-14 | 10K | 29K | 34.3% | 0 |
| 2026-10-13 | 5K | 6K | 90.2% | 0 |
| 2026-10-12 | 1K | 2K | 51.2% | 0 |
| 2026-10-09 | 12K | 20K | 62.2% | 0 |
| 2026-10-08 | 13K | 30K | 45.4% | 561 |
| 2026-10-07 | 3K | 12K | 28.5% | 77 |
| 2026-10-06 | 408 | 2K | 18.0% | 0 |
| 2026-10-05 | 10K | 19K | 52.2% | 180 |
| 2026-10-02 | 794 | 5K | 16.3% | 0 |
| 2026-10-01 | 4K | 12K | 35.8% | 0 |
| 2026-09-30 | 1K | 2K | 71.8% | 0 |
| 2026-09-29 | 1K | 4K | 34.2% | 0 |
| 2026-09-28 | 3K | 5K | 47.5% | 0 |
| 2026-09-25 | 3K | 17K | 18.0% | 699 |
| 2026-09-24 | 7K | 8K | 84.9% | 0 |
| 2026-09-23 | 12K | 28K | 45.2% | 0 |
| 2026-09-22 | 24K | 31K | 78.3% | 0 |
| 2026-09-21 | 6K | 13K | 43.1% | 0 |
| 2026-09-18 | 3K | 8K | 32.8% | 0 |
| 2026-09-17 | 13K | 18K | 69.5% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in CPIX is 105 shares, down 173 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (14 May 2026) to 28,500 shares (24 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 105 | $7.65 | $803 |
| 2026-09-24 | 278 | $7.94 | $2K |
| 2026-09-23 | 5 | $8.20 | $41 |
| 2026-09-18 | 4 | $7.19 | $29 |
| 2026-08-25 | 4 | $7.84 | $31 |
| 2026-08-24 | 28,500 | $7.65 | $218K |
| 2026-08-20 | 514 | $7.65 | $4K |
| 2026-08-18 | 533 | $7.68 | $4K |
| 2026-08-04 | 1,749 | $7.18 | $13K |
| 2026-07-30 | 1,355 | $6.66 | $9K |
| 2026-07-24 | 21 | $6.99 | $147 |
| 2026-07-20 | 9,500 | $6.84 | $65K |
| 2026-07-14 | 2,603 | $6.54 | $17K |
| 2026-07-02 | 1,351 | $7.13 | $10K |
| 2026-06-30 | 1 | $6.84 | $7 |
| 2026-06-22 | 18,500 | $5.72 | $106K |
| 2026-06-05 | 172 | $5.84 | $1K |
| 2026-06-04 | 172 | $5.61 | $965 |
| 2026-06-02 | 1,608 | $5.70 | $9K |
| 2026-05-26 | 9,893 | $5.87 | $58K |
| 2026-05-22 | 17,197 | $5.51 | $95K |
| 2026-05-21 | 10,503 | $5.53 | $58K |
| 2026-05-20 | 3 | $5.41 | $16 |
| 2026-05-18 | 6,935 | $5.47 | $38K |
| 2026-05-14 | 1 | $4.85 | $5 |
| 2026-05-13 | 31 | $4.53 | $140 |
| 2026-05-08 | 422 | $4.29 | $2K |
| 2026-05-07 | 500 | $4.37 | $2K |
| 2026-05-06 | 4,616 | $4.55 | $21K |
| 2026-05-04 | 576 | $4.36 | $3K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for CPIX in the last 90 days. The most recent filings are listed below. Latest filing: Galante Joseph C (Director) on 2026-03-18.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-03-18 | Galante Joseph C | Director | Grant | 2K | $2.80 | $5K | 64K |
| 2026-03-18 | Jones James | Director | Grant | 2K | $2.80 | $5K | 47K |
| 2026-03-18 | Krogulski Kenneth | Director | Grant | 4K | $2.80 | $11K | 302K |
| 2026-03-18 | Krogulski Kenneth | Director | Grant | 2K | $2.80 | $5K | 298K |
| 2026-03-18 | Young Caroline | Director | Grant | 2K | $2.80 | $5K | 35K |
| 2026-03-18 | Brown Martin S JR | Director | Grant | 2K | $2.80 | $5K | 10K |
| 2026-03-16 | KAZIMI A J | Chairman and CEO | Tax withholding | 6K | $3.06 | $18K | 5.7M |
| 2025-12-31 | Young Caroline | Director | Small acquisition | 5 | $3.91 | $20 | 33K |
| 2025-12-31 | Jones James | Director | Small acquisition | 7 | $3.91 | $27 | 45K |
| 2025-12-31 | KAZIMI A J | Chairman and CEO | Small acquisition | 7 | $3.91 | $27 | 5.7M |
| 2025-12-31 | Krogulski Kenneth | Director | Small acquisition | 62 | $3.91 | $242 | 297K |
| 2025-12-30 | Young Caroline | Director | Small acquisition | 2 | $3.94 | $8 | 33K |
| 2025-12-30 | Jones James | Director | Small acquisition | 8 | $3.94 | $32 | 45K |
| 2025-12-30 | KAZIMI A J | Chairman and CEO | Small acquisition | 8 | $3.94 | $32 | 5.7M |
| 2025-12-30 | Krogulski Kenneth | Director | Small acquisition | 54 | $3.94 | $213 | 296K |
| 2025-12-29 | Young Caroline | Director | Small acquisition | 2 | $4.01 | $8 | 33K |
| 2025-12-29 | Jones James | Director | Small acquisition | 8 | $4.01 | $32 | 45K |
| 2025-12-29 | KAZIMI A J | Chairman and CEO | Small acquisition | 8 | $4.01 | $32 | 5.7M |
| 2025-12-29 | Krogulski Kenneth | Director | Small acquisition | 54 | $4.01 | $217 | 296K |
| 2025-12-26 | Young Caroline | Director | Small acquisition | 2 | $4.21 | $8 | 33K |
| 2025-12-26 | Jones James | Director | Small acquisition | 8 | $4.21 | $34 | 45K |
| 2025-12-26 | KAZIMI A J | Chairman and CEO | Small acquisition | 8 | $4.21 | $34 | 5.7M |
| 2025-12-26 | Krogulski Kenneth | Director | Small acquisition | 54 | $4.21 | $227 | 296K |
| 2025-12-24 | Young Caroline | Director | Small acquisition | 2 | $4.26 | $9 | 33K |
| 2025-12-24 | Jones James | Director | Small acquisition | 8 | $4.26 | $34 | 45K |
| 2025-12-24 | KAZIMI A J | Chairman and CEO | Small acquisition | 8 | $4.26 | $34 | 5.7M |
| 2025-12-24 | Krogulski Kenneth | Director | Small acquisition | 54 | $4.26 | $230 | 296K |
| 2025-12-23 | Young Caroline | Director | Small acquisition | 2 | $4.13 | $8 | 33K |
| 2025-12-23 | Jones James | Director | Small acquisition | 8 | $4.13 | $33 | 45K |
| 2025-12-23 | KAZIMI A J | Chairman and CEO | Small acquisition | 8 | $4.13 | $33 | 5.7M |
| 2025-12-23 | Krogulski Kenneth | Director | Small acquisition | 54 | $4.13 | $223 | 296K |
| 2025-12-22 | Young Caroline | Director | Small acquisition | 2 | $4.32 | $9 | 33K |
| 2025-12-22 | Jones James | Director | Small acquisition | 7 | $4.32 | $30 | 45K |
| 2025-12-22 | KAZIMI A J | Chairman and CEO | Small acquisition | 7 | $4.32 | $30 | 5.7M |
| 2025-12-22 | Krogulski Kenneth | Director | Small acquisition | 50 | $4.32 | $216 | 296K |
| 2025-12-19 | Young Caroline | Director | Small acquisition | 2 | $4.19 | $8 | 33K |
| 2025-12-19 | Jones James | Director | Small acquisition | 8 | $4.19 | $34 | 45K |
| 2025-12-19 | KAZIMI A J | Chairman and CEO | Small acquisition | 8 | $4.19 | $34 | 5.7M |
| 2025-12-19 | Krogulski Kenneth | Director | Small acquisition | 52 | $4.19 | $218 | 296K |
| 2025-12-18 | Young Caroline | Director | Small acquisition | 3 | $4.19 | $13 | 33K |
| 2025-12-18 | Jones James | Director | Small acquisition | 10 | $4.19 | $42 | 45K |
| 2025-12-18 | KAZIMI A J | Chairman and CEO | Small acquisition | 10 | $4.19 | $42 | 5.7M |
| 2025-12-18 | Krogulski Kenneth | Director | Small acquisition | 67 | $4.19 | $281 | 296K |
| 2025-12-17 | Young Caroline | Director | Small acquisition | 3 | $3.65 | $11 | 33K |
| 2025-12-17 | Jones James | Director | Small acquisition | 10 | $3.65 | $37 | 45K |
| 2025-12-17 | KAZIMI A J | Chairman and CEO | Small acquisition | 10 | $3.65 | $37 | 5.7M |
| 2025-12-17 | Krogulski Kenneth | Director | Small acquisition | 67 | $3.65 | $245 | 296K |
| 2025-12-16 | Young Caroline | Director | Small acquisition | 3 | $3.27 | $10 | 33K |
| 2025-12-16 | Jones James | Director | Small acquisition | 14 | $3.27 | $46 | 45K |
| 2025-12-16 | KAZIMI A J | Chairman and CEO | Small acquisition | 14 | $3.27 | $46 | 5.7M |
| 2025-12-16 | Krogulski Kenneth | Director | Small acquisition | 104 | $3.27 | $340 | 296K |
| 2025-12-15 | Young Caroline | Director | Small acquisition | 3 | $2.82 | $8 | 33K |
| 2025-12-15 | Jones James | Director | Small acquisition | 14 | $2.82 | $39 | 45K |
| 2025-12-15 | KAZIMI A J | Chairman and CEO | Small acquisition | 14 | $2.82 | $39 | 5.7M |
| 2025-12-15 | Krogulski Kenneth | Director | Small acquisition | 104 | $2.82 | $293 | 296K |
| 2025-12-12 | Young Caroline | Director | Small acquisition | 3 | $2.50 | $8 | 33K |
| 2025-12-12 | Jones James | Director | Small acquisition | 14 | $2.50 | $35 | 45K |
| 2025-12-12 | KAZIMI A J | Chairman and CEO | Small acquisition | 14 | $2.50 | $35 | 5.7M |
| 2025-12-12 | Krogulski Kenneth | Director | Small acquisition | 104 | $2.50 | $260 | 296K |
| 2025-12-11 | Young Caroline | Director | Small acquisition | 3 | $2.56 | $8 | 33K |
| 2025-12-11 | Jones James | Director | Small acquisition | 14 | $2.56 | $36 | 45K |
| 2025-12-11 | KAZIMI A J | Chairman and CEO | Small acquisition | 14 | $2.56 | $36 | 5.7M |
| 2025-12-11 | Krogulski Kenneth | Director | Small acquisition | 104 | $2.56 | $266 | 296K |
| 2025-12-10 | Young Caroline | Director | Small acquisition | 3 | $2.60 | $8 | 33K |
| 2025-12-10 | Jones James | Director | Small acquisition | 14 | $2.60 | $36 | 45K |
| 2025-12-10 | KAZIMI A J | Chairman and CEO | Small acquisition | 14 | $2.60 | $36 | 5.7M |
| 2025-12-10 | Krogulski Kenneth | Director | Small acquisition | 104 | $2.60 | $270 | 296K |
| 2025-12-09 | Young Caroline | Director | Small acquisition | 3 | $2.32 | $7 | 33K |
| 2025-12-09 | Jones James | Director | Small acquisition | 14 | $2.32 | $32 | 45K |
| 2025-12-09 | KAZIMI A J | Chairman and CEO | Small acquisition | 14 | $2.32 | $32 | 5.7M |
| 2025-12-09 | Krogulski Kenneth | Director | Small acquisition | 104 | $2.32 | $241 | 295K |
| 2025-12-08 | Young Caroline | Director | Small acquisition | 3 | $2.40 | $7 | 33K |
| 2025-12-08 | Jones James | Director | Small acquisition | 14 | $2.40 | $34 | 45K |
| 2025-12-08 | KAZIMI A J | Chairman and CEO | Small acquisition | 14 | $2.40 | $34 | 5.7M |
| 2025-12-08 | Krogulski Kenneth | Director | Small acquisition | 104 | $2.40 | $250 | 295K |
| 2025-12-05 | Young Caroline | Director | Small acquisition | 4 | $2.34 | $9 | 33K |
| 2025-12-05 | Jones James | Director | Small acquisition | 18 | $2.34 | $42 | 45K |
| 2025-12-05 | KAZIMI A J | Chairman and CEO | Small acquisition | 18 | $2.34 | $42 | 5.7M |
| 2025-12-05 | Krogulski Kenneth | Director | Small acquisition | 124 | $2.34 | $290 | 295K |
| 2025-12-04 | Young Caroline | Director | Small acquisition | 4 | $2.27 | $9 | 33K |
| 2025-12-04 | Jones James | Director | Small acquisition | 18 | $2.27 | $41 | 45K |
| 2025-12-04 | KAZIMI A J | Chairman and CEO | Small acquisition | 18 | $2.27 | $41 | 5.7M |
| 2025-12-04 | Krogulski Kenneth | Director | Small acquisition | 124 | $2.27 | $281 | 295K |
| 2025-12-03 | Young Caroline | Director | Small acquisition | 4 | $2.25 | $9 | 33K |
| 2025-12-03 | Jones James | Director | Small acquisition | 18 | $2.25 | $41 | 45K |
| 2025-12-03 | KAZIMI A J | Chairman and CEO | Small acquisition | 18 | $2.25 | $41 | 5.7M |
| 2025-12-03 | Krogulski Kenneth | Director | Small acquisition | 124 | $2.25 | $279 | 295K |
| 2025-12-02 | Young Caroline | Director | Small acquisition | 4 | $2.24 | $9 | 33K |
| 2025-12-02 | Jones James | Director | Small acquisition | 18 | $2.24 | $40 | 45K |
| 2025-12-02 | KAZIMI A J | Chairman and CEO | Small acquisition | 18 | $2.24 | $40 | 5.7M |
| 2025-12-02 | Krogulski Kenneth | Director | Small acquisition | 124 | $2.24 | $278 | 295K |
| 2025-12-01 | Young Caroline | Director | Small acquisition | 4 | $2.36 | $9 | 33K |
| 2025-12-01 | Jones James | Director | Small acquisition | 18 | $2.36 | $42 | 45K |
| 2025-12-01 | KAZIMI A J | Chairman and CEO | Small acquisition | 18 | $2.36 | $42 | 5.7M |
| 2025-12-01 | Krogulski Kenneth | Director | Small acquisition | 124 | $2.36 | $293 | 295K |
| 2025-11-28 | Jones James | Director | Small acquisition | 18 | $2.41 | $43 | 45K |
| 2025-11-28 | Young Caroline | Director | Small acquisition | 4 | $2.41 | $10 | 33K |
| 2025-11-28 | KAZIMI A J | Chairman and CEO | Small acquisition | 18 | $2.41 | $43 | 5.7M |
| 2025-11-28 | Krogulski Kenneth | Director | Small acquisition | 124 | $2.41 | $299 | 295K |
| 2025-11-26 | Jones James | Director | Small acquisition | 18 | $2.17 | $39 | 45K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of CPIX in its latest filing, on Schedule 13G (passive). The holder is A.J. Kazimi at 38.4% of the class (5,789,155 shares), filed 2026-02-09 for an event on 2026-01-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-02-09 | 13G | A.J. Kazimiindividual | 5.8M | 38.4% | 2026-01-30 |
| 2025-10-30 | 13G/Ano. 2 | Integrated Core Strategies (US) LLCother entity | 599K | 4.0% | 2025-09-30 |
| 2025-10-30 | 13G/Ano. 2 | Millennium Management LLCother entity | 599K | 4.0% | 2025-09-30 |
| 2025-10-30 | 13G/Ano. 2 | Millennium Group Management LLCother entity | 599K | 4.0% | 2025-09-30 |
| 2025-10-30 | 13G/Ano. 2 | Israel A. Englanderindividual | 599K | 4.0% | 2025-09-30 |
13F holders
Tracked managers holding CPIX at their latest 13F. JSON3 of the 30 tracked managers held CPIX at their latest 13F, $3.7M in total at quarter-end prices. Renaissance Technologies is the largest at $3.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 478K | $3.1M | 0.00% | +8K |
| Citadel Advisors | 2026-06-30 | 73K | $476K | 0.00% | +57K |
| Two Sigma Investments | 2026-06-30 | 24K | $155K | 0.00% | +13K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Cumberland Pharmaceuticals reported revenue of $8.8M, down 18.8% from the same quarter a year earlier, and net loss of $4.3M (-0.29 diluted EPS). In FY 2025 it generated $4.9M of operating cash flow and spent $263K on buybacks.
- Cash
- $3.9M
- Equity
- $17.4M
- Total assets
- $62.9M
- Shares outstanding
- 14,983,107
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $8.8M | -$4.3M | -48.6% | -0.29 |
| Q1 FY 2026 | 2026-03-31 | $9.1M | -$3.3M | -36.0% | -0.22 |
| Q4 FY 2025 | 2025-12-31 | $13.7M | -$1.4M | -10.3% | -0.09 |
| Q3 FY 2025 | 2025-09-30 | $8.3M | -$1.9M | -23.4% | -0.13 |
| Q2 FY 2025 | 2025-06-30 | $10.8M | -$741K | -6.8% | -0.05 |
| Q1 FY 2025 | 2025-03-31 | $11.7M | $1.3M | 10.7% | 0.08 |
| Q4 FY 2024 | 2024-12-31 | $10.4M | -$1.9M | -18.2% | -0.14 |
| Q3 FY 2024 | 2024-09-30 | $9.1M | -$1.5M | -17.0% | -0.11 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $44.5M | -$2.8M | $4.9M | $98K | $263K | n/a |
| FY 2024 | 2024-12-31 | $37.9M | -$6.5M | -$612K | $66K | $579K | n/a |
| FY 2023 | 2023-12-31 | $39.6M | -$6.3M | $6.1M | $281K | $741K | n/a |
| FY 2022 | 2022-12-31 | $42.0M | -$5.6M | $8.5M | $102K | $1.1M | n/a |
| FY 2021 | 2021-12-31 | $35.0M | -$3.5M | $6.3M | $104K | $1.4M | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-05 from the cover page.
What this page is
Cumberland Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Cumberland Pharmaceuticals (CPIX), SEC CIK 1087294, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-02-09.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-03-18.JSON and CSV
- Company record
- EDGAR filing index for CIK 1087294Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of CPIX is sold short?
What is CPIX's daily short volume?
Does CPIX have fails to deliver?
Are CPIX insiders buying or selling?
Who owns 5% or more of CPIX?
What did CPIX report last quarter?
Which tracked 13F managers own CPIX?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.